GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-06-27|

Amai Proteins, producer of 100% protein sweetener that reduces sugar in Food & Beverages by up to 70%, voted Global Winner at the 2022 Extreme Tech Challenge Competition

by GeneOnline
Share To
 

PALO ALTO, Calif., June 28, 2022 /PRNewswire/ — Amai Proteins, an Israeli start-up developer of novel designer proteins that answer the needs of consumers and industry, is the Global Winner of the 2022 XTC competition. Extreme Tech Challenge (XTC) is the world’s largest start-up competition for purpose-driven companies. Over 2000+ start-ups from 100+ countries competed in 10 impact areas ranging from Biotech to Education, Fintech to Cleantech, etc.

Sugar overconsumption underlies the Metabolic Syndrome (obesity, diabetes, and more), a global health challenge primarily affecting the lower socioeconomic classes. Sugar production also places a significant burden on arable land and water usage, contributing air, land, and sea pollution.

Dr. Ilan Samish, CEO and Founder said: “Amai – ‘sweet’ in Japanese – produces a great tasting and market-fit 100% protein sweetener via Amai’s Pro3 Platform: Pro-Design AI-CPD (Computational Protein Design), Pro-Planet precision fermentation, and Pro-Taste food technology.

Our first product, sweelinTM, is a sustainable, 100% sweet protein that can reduce 40% to 70% of added sugar in a wide variety of food & beverages, without changing the consumer taste experience. The novel proteins mimic proteins that reside in harsh conditions (e.g., Dead Sea, hot springs, acidic swamps) and are thus fit for the requirements for the mass food market. These include soft drinks, fruit juices, dairy, alternative dairy products, sauces, spreads, snacks, ketchup, chocolate, peanut butter, energy bars, functional foods, and much more.

Amai’s sweelinTM combines cost-effectiveness with significant impact improvements both for the health of our people and the health of our planet.”

About Amai Proteins
Amai Proteins develops novel designer proteins that answer the needs of consumers and industry. The first product, sweelinTM, is a 100% sweet protein designed to significantly replace sugar and sugar alternatives in a wide variety of food & beverages including soft drinks, fruit juice, dairy products, sauces, spreads, dressings, snacks, peanut butter, and much more. Our solutions are inspired by nature and built with biology through a natural fermentation process. With our Pro3 platform, Amai Proteins aims to create future breakthroughs in the world of meat, plant, and milk proteins.

To learn more visit: www.amaiproteins.com, visit our official LinkedIn and YouTube channels. 

About XTC Extreme Tech Challenge
TECH FOR PURPOSE: XTC is a non-profit organization behind the world’s biggest startup competition that aims to help startups change the world for the better. In our quest, we are supported by leading corporations, VCs, foundations, policymakers, universities, and tech conferences. The Extreme Tech Challenge impact competition assesses startups around the world with a focus on the 17 Sustainability Development Goals (SDGs) set by the United Nations along with other criteria – level of innovation, market fitness and team quality. The Extreme Tech Challenge 2022 Global Finals presented by TechCrunch Session Climate was attended by an audience of 1600+ in person and remote attendees.
https://extremetechchallenge.org 

For more information:
Dr. Ilan Samish, Founder & CEO, Amai Proteins
[email protected]

 

Dr. Ilan Samish (right), founder and CEO at Amai Proteins, Grand Winner of the Extreme Tech Challenge XTC 2022 competition.
Dr. Ilan Samish (right), founder and CEO at Amai Proteins, Grand Winner of the Extreme Tech Challenge XTC 2022 competition.

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top